116 related articles for article (PubMed ID: 10885607)
1. Up-front chemotherapy with fotemustine (F) / cisplatin (CDDP) / etoposide (VP16) regimen in the treatment of 33 non-removable glioblastomas.
Frenay M; Lebrun C; Lonjon M; Bondiau PY; Chatel M
Eur J Cancer; 2000 May; 36(8):1026-31. PubMed ID: 10885607
[TBL] [Abstract][Full Text] [Related]
2. [Chemotherapy of malignant inoperable gliomas. The association of fotemustine-cisplatine-etoposide as neoadjuvants].
Frenay M; Lebrun C; Lonjon M; Marcy PY; Paquis P
Rev Neurol (Paris); 2000 Jan; 156(1):53-8. PubMed ID: 10693259
[TBL] [Abstract][Full Text] [Related]
3. Neoadjuvant cisplatin and etoposide, with or without tamoxifen, prior to radiotherapy in high-grade gliomas: a single-center experience.
Díaz R; Jordá MV; Reynés G; Aparicio J; Segura A; Amador R; Calderero V; Beltrán A
Anticancer Drugs; 2005 Mar; 16(3):323-9. PubMed ID: 15711185
[TBL] [Abstract][Full Text] [Related]
4. Treatment of newly diagnosed glioblastoma multiforme with carmustine, cisplatin and etoposide followed by radiotherapy. A phase II study.
Lassen U; Kristjansen PE; Wagner A; Kosteljanetz M; Poulsen HS
J Neurooncol; 1999 Jun; 43(2):161-6. PubMed ID: 10533728
[TBL] [Abstract][Full Text] [Related]
5. Cisplatin, dacarbazine, and fotemustine plus interferon alpha in patients with advanced malignant melanoma. A multicenter phase II study of the Italian Cooperative Oncology Group.
Daponte A; Ascierto PA; Gravina A; Melucci MT; Palmieri G; Comella P; Cellerino R; DeLena M; Marini G; Comella G;
Cancer; 2000 Dec; 89(12):2630-6. PubMed ID: 11135225
[TBL] [Abstract][Full Text] [Related]
6. Cisplatin-fotemustine combination in inoperable non-small cell lung cancer: preliminary report of a French multicentre phase II trial.
Rivière A; Le Cesne A; Berille J; Baio S; Le Chevalier T
Eur J Cancer; 1994; 30A(5):587-90. PubMed ID: 8080671
[TBL] [Abstract][Full Text] [Related]
7. [Differentiated treatment protocols for high- and standard-risk hepatoblastoma--an interim report of the German Liver Tumor Study HB99].
Häberle B; Bode U; von Schweinitz D
Klin Padiatr; 2003; 215(3):159-65. PubMed ID: 12778356
[TBL] [Abstract][Full Text] [Related]
8. A randomized trial between two neoadjuvant chemotherapy protocols: CDDP + 5-FU versus CDDP + VP16 in advanced cancer of the head and neck.
Prévost A; Mérol JC; Aimé P; Moutel K; Roger-Liautaud F; Nasca S; Legros M; Coninx P
Oncol Rep; 2005 Sep; 14(3):771-6. PubMed ID: 16077990
[TBL] [Abstract][Full Text] [Related]
9. A phase II trial of fotemustine and cisplatin in central nervous system metastases from non-small cell lung cancer.
Cotto C; Berille J; Souquet PJ; Riou R; Croisile B; Turjman F; Giroux B; Brune J; Trillet-Lenoir V
Eur J Cancer; 1996 Jan; 32A(1):69-71. PubMed ID: 8695244
[TBL] [Abstract][Full Text] [Related]
10. Second-line chemotherapy with dacarbazine and fotemustine in nitrosourea-pretreated patients with recurrent glioblastoma multiforme.
Fazeny-Dörner B; Veitl M; Wenzel C; Piribauer M; Rössler K; Dieckmann K; Ungersböck K; Marosi C
Anticancer Drugs; 2003 Jul; 14(6):437-42. PubMed ID: 12853885
[TBL] [Abstract][Full Text] [Related]
11. Nitroso-urea-cisplatin-based chemotherapy associated with valproate: increase of haematologic toxicity.
Bourg V; Lebrun C; Chichmanian RM; Thomas P; Frenay M
Ann Oncol; 2001 Feb; 12(2):217-9. PubMed ID: 11300327
[TBL] [Abstract][Full Text] [Related]
12. Concurrent radiotherapy: fotemustine combination for newly diagnosed malignant glioma patients, a phase II study.
Beauchesne PD; Taillandier L; Bernier V; Carnin C
Cancer Chemother Pharmacol; 2009 Jun; 64(1):171-5. PubMed ID: 19352662
[TBL] [Abstract][Full Text] [Related]
13. Salvage chemotherapy with procarbazine and fotemustine combination in the treatment of temozolomide treated recurrent glioblastoma patients.
Silvani A; Lamperti E; Gaviani P; Eoli M; Fiumani A; Salmaggi A; Falcone C; Filippini G; Botturi A; Boiardi A
J Neurooncol; 2008 Apr; 87(2):143-51. PubMed ID: 17576523
[TBL] [Abstract][Full Text] [Related]
14. Fotemustine in the treatment of brain primary tumors and metastases.
Khayat D; Giroux B; Berille J; Cour V; Gerard B; Sarkany M; Bertrand P; Bizzari JP
Cancer Invest; 1994; 12(4):414-20. PubMed ID: 8032964
[TBL] [Abstract][Full Text] [Related]
15. Toxicities related to intraarterial infusion of cisplatin and etoposide in patients with brain tumors.
Tfayli A; Hentschel P; Madajewicz S; Manzione J; Chowhan N; Davis R; Roche P; Iliya A; Roque C; Meek A; Shady M
J Neurooncol; 1999 Mar; 42(1):73-7. PubMed ID: 10360481
[TBL] [Abstract][Full Text] [Related]
16. The effects of sequential versus concurrent chemotherapy and radiotherapy on survival and toxicity in patients with newly diagnosed high-grade astrocytoma.
Kleinberg L; Grossman SA; Piantadosi S; Zeltzman M; Wharam M
Int J Radiat Oncol Biol Phys; 1999 Jun; 44(3):535-43. PubMed ID: 10348282
[TBL] [Abstract][Full Text] [Related]
17. ACNU-cisplatin continuous infusion chemotherapy as salvage therapy for recurrent glioblastomas: phase II study.
Gwak HS; Youn SM; Kwon AH; Lee SH; Kim JH; Rhee CH
J Neurooncol; 2005 Nov; 75(2):173-80. PubMed ID: 16132508
[TBL] [Abstract][Full Text] [Related]
18. Phase III randomized study of postradiotherapy chemotherapy with alpha-difluoromethylornithine-procarbazine, N-(2-chloroethyl)-N'-cyclohexyl-N-nitrosurea, vincristine (DFMO-PCV) versus PCV for glioblastoma multiforme.
Levin VA; Uhm JH; Jaeckle KA; Choucair A; Flynn PJ; Yung WKA ; Prados MD; Bruner JM; Chang SM; Kyritsis AP; Gleason MJ; Hess KR
Clin Cancer Res; 2000 Oct; 6(10):3878-84. PubMed ID: 11051233
[TBL] [Abstract][Full Text] [Related]
19. Concurrent cisplatin, etoposide, and radiotherapy for unresectable stage III nonsmall cell lung cancer: a phase II study.
Reboul F; Brewer Y; Vincent P; Chauvet B; Faure CF; Taulelle M
Int J Radiat Oncol Biol Phys; 1996 May; 35(2):343-50. PubMed ID: 8635942
[TBL] [Abstract][Full Text] [Related]
20. Pilot study of cyclophosphamide-doxorubicin-vincristine-cisplatin-etoposide hybrid chemotherapy in small cell lung cancer.
Ohnoshi T; Hiraki S; Ueoka H; Kiura K; Kamei H; Horiguchi T; Kodani T; Maeda T; Tabata M; Shibayama T
Cancer; 1993 Sep; 72(5):1597-601. PubMed ID: 8394202
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
